Candel Therapeutics, Inc. CADL
8.82 USD +0.70 (+8.62%)
At closeNov 4, 2026, 5:57 AM EST
8.71 -0.11 -1.25%
Pre-market · Nov 4, 5:57 AM ET
8.19 Day range 8.86
4.35 52-week range 14.00
- YTD
- +56.11%
- 1 year
- +68.97%
News
globenewswire.com Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients…
globenewswire.com Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal…
benzinga.com Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25 Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $25.